<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/atom10full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><feed xmlns="http://www.w3.org/2005/Atom" xmlns:thr="http://purl.org/syndication/thread/1.0" xml:lang="en-US" xml:base="http://www.bio-wire.com/wp-atom.php">
	<title type="text">Bio-Wire - Small Pharma &amp; Biotech News, FDA Catalysts, Trade Ideas, And More</title>
	<subtitle type="text">Wall Street's News Portal for Small Pharma &amp; Biotech</subtitle>

	<updated>2013-01-30T14:41:25Z</updated>

	<link rel="alternate" type="text/html" href="http://www.bio-wire.com" />
	<id>http://www.bio-wire.com/feed/atom</id>
	

	<generator uri="http://wordpress.org/" version="3.4.2">WordPress</generator>
		<atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/atom+xml" href="http://feeds.feedburner.com/HyperionCapitalResearch" /><feedburner:info xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" uri="hyperioncapitalresearch" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><entry>
		<author>
			<name>Brian L. Wilson</name>
					</author>
		<title type="html"><![CDATA[4 Small Biotechs With Big Clinical Trials Presenting In 2013]]></title>
		<link rel="alternate" type="text/html" href="http://www.bio-wire.com/archives/736" />
		<id>http://www.bio-wire.com/?p=736</id>
		<updated>2013-01-30T14:41:25Z</updated>
		<published>2013-01-30T14:41:25Z</published>
		<category scheme="http://www.bio-wire.com" term="Brian L. Wilson" /><category scheme="http://www.bio-wire.com" term="ADXS" /><category scheme="http://www.bio-wire.com" term="AEZS" /><category scheme="http://www.bio-wire.com" term="APPY" /><category scheme="http://www.bio-wire.com" term="LJPC" />		<summary type="html"><![CDATA[Here are a few small biotechs that are at vital stages in their clinical development process, and will provide some results this year. They are arranged in estimated chronological order, meaning that the most immediate catalysts/data releases are higher on the list. 1.) AEterna Zentaris (NASDAQ: AEZS) - the company stock shot up over 17% on Tuesday, January [...]]]></summary>
		<link rel="replies" type="text/html" href="http://www.bio-wire.com/archives/736#comments" thr:count="0" />
		<link rel="replies" type="application/atom+xml" href="http://www.bio-wire.com/archives/736/feed/atom" thr:count="0" />
		<thr:total>0</thr:total>
	</entry>
		<entry>
		<author>
			<name>Scott Matusow</name>
						<uri>http://scottmatusow.com/</uri>
					</author>
		<title type="html"><![CDATA[EnteroMedics&#8217; Late Stage Treatment Takes on Obesity Epidemic]]></title>
		<link rel="alternate" type="text/html" href="http://www.bio-wire.com/archives/733" />
		<id>http://www.bio-wire.com/?p=733</id>
		<updated>2013-01-30T06:19:02Z</updated>
		<published>2013-01-30T06:19:02Z</published>
		<category scheme="http://www.bio-wire.com" term="Scott Matusow" /><category scheme="http://www.bio-wire.com" term="ETRM" />		<summary type="html"><![CDATA[Our focus turns to EnteroMedics, which offers a new treatment approach currently in Phase III clinical trials, designed to help morbidly obese people lose weight. EnteroMedics&#8217; approach may be a better solution for people who see little or no benefit from current treatments on the market. If the device proves successful, the company could end up being [...]]]></summary>
		<link rel="replies" type="text/html" href="http://www.bio-wire.com/archives/733#comments" thr:count="0" />
		<link rel="replies" type="application/atom+xml" href="http://www.bio-wire.com/archives/733/feed/atom" thr:count="0" />
		<thr:total>0</thr:total>
	</entry>
		<entry>
		<author>
			<name>Brian L. Wilson</name>
					</author>
		<title type="html"><![CDATA[Keryx &#8211; Take The Money And Run?]]></title>
		<link rel="alternate" type="text/html" href="http://www.bio-wire.com/archives/725" />
		<id>http://www.bio-wire.com/?p=725</id>
		<updated>2013-01-29T22:44:17Z</updated>
		<published>2013-01-29T22:43:39Z</published>
		<category scheme="http://www.bio-wire.com" term="Brian L. Wilson" /><category scheme="http://www.bio-wire.com" term="KERX" />		<summary type="html"><![CDATA[Shares of Keryx Biopharmaceuticals (NASDAQ: KERX) rocketed upwards yesterday due to phase III results that were release on a conference call before the bell. The data, which took a few extra weeks to hit the public, showed that Keryx&#8217;s phosphate-binding drug Zerenex was “not inferior” regarding phosphate reduction in patients with late-stage kidney disease when compared to [...]]]></summary>
		<link rel="replies" type="text/html" href="http://www.bio-wire.com/archives/725#comments" thr:count="0" />
		<link rel="replies" type="application/atom+xml" href="http://www.bio-wire.com/archives/725/feed/atom" thr:count="0" />
		<thr:total>0</thr:total>
	</entry>
		<entry>
		<author>
			<name>Scott Matusow</name>
						<uri>http://scottmatusow.com/</uri>
					</author>
		<title type="html"><![CDATA[EnteroMedics (ETRM) Basic DD and Thesis]]></title>
		<link rel="alternate" type="text/html" href="http://www.bio-wire.com/archives/719" />
		<id>http://www.bio-wire.com/?p=719</id>
		<updated>2013-01-28T18:42:53Z</updated>
		<published>2013-01-28T18:42:53Z</published>
		<category scheme="http://www.bio-wire.com" term="Scott Matusow" /><category scheme="http://www.bio-wire.com" term="ETRM" />		<summary type="html"><![CDATA[EnteroMedics Inc. (ETRM) I bought a nice amount of shares. Catalyst trade run up target opinion: $.4.40. Positive data release: Gap to $7. 1 year: $15 (my opinions only) According to company press releases, conference calls, and my correspondence with investor relations, Phase III data from its Recharge study on its flagship product, The Maestro System, is [...]]]></summary>
		<link rel="replies" type="text/html" href="http://www.bio-wire.com/archives/719#comments" thr:count="0" />
		<link rel="replies" type="application/atom+xml" href="http://www.bio-wire.com/archives/719/feed/atom" thr:count="0" />
		<thr:total>0</thr:total>
	</entry>
		<entry>
		<author>
			<name>Scott Matusow</name>
						<uri>http://scottmatusow.com/</uri>
					</author>
		<title type="html"><![CDATA[Weekend Update: $CORT $ATHX $CLSN $BLRX $NEPT + Chart Analysis And Explanation]]></title>
		<link rel="alternate" type="text/html" href="http://www.bio-wire.com/archives/716" />
		<id>http://www.bio-wire.com/?p=716</id>
		<updated>2013-01-28T18:41:32Z</updated>
		<published>2013-01-28T18:40:03Z</published>
		<category scheme="http://www.bio-wire.com" term="Scott Matusow" /><category scheme="http://www.bio-wire.com" term="ATHX" /><category scheme="http://www.bio-wire.com" term="BLRX" /><category scheme="http://www.bio-wire.com" term="CLSN" /><category scheme="http://www.bio-wire.com" term="CORT" /><category scheme="http://www.bio-wire.com" term="NEPT" />		<summary type="html"><![CDATA[In this video, I review a couple of charts, and review  a couple of my trade calls. Chart analysis and explanation offered. Hope you find the video educational!  Scott &#160; &#160;]]></summary>
		<link rel="replies" type="text/html" href="http://www.bio-wire.com/archives/716#comments" thr:count="0" />
		<link rel="replies" type="application/atom+xml" href="http://www.bio-wire.com/archives/716/feed/atom" thr:count="0" />
		<thr:total>0</thr:total>
	</entry>
		<entry>
		<author>
			<name>Brian L. Wilson</name>
					</author>
		<title type="html"><![CDATA[Sarepta Recovers Lost Ground From Bullish Analyst Activity]]></title>
		<link rel="alternate" type="text/html" href="http://www.bio-wire.com/archives/712" />
		<id>http://www.bio-wire.com/?p=712</id>
		<updated>2013-01-28T08:08:43Z</updated>
		<published>2013-01-28T08:08:43Z</published>
		<category scheme="http://www.bio-wire.com" term="Brian L. Wilson" /><category scheme="http://www.bio-wire.com" term="KERX" />		<summary type="html"><![CDATA[Sarepta Therapeutics (NASDAQ: SRPT), formerly known as AVI BioPharma, is the developer of the promising new treatment for Duchenne Muscular Dystrophy (DMD) – a  rare and devastating genetic disorder that occurs in roughly 1 out of every 6,000 births. There are multiple types of muscular dystrophy, although Duchenne in particular is the most common. Children [...]]]></summary>
		<link rel="replies" type="text/html" href="http://www.bio-wire.com/archives/712#comments" thr:count="0" />
		<link rel="replies" type="application/atom+xml" href="http://www.bio-wire.com/archives/712/feed/atom" thr:count="0" />
		<thr:total>0</thr:total>
	</entry>
		<entry>
		<author>
			<name>Brian L. Wilson</name>
					</author>
		<title type="html"><![CDATA[Why Z160 Will Make Or Break Zalicus]]></title>
		<link rel="alternate" type="text/html" href="http://www.bio-wire.com/archives/707" />
		<id>http://www.bio-wire.com/?p=707</id>
		<updated>2013-01-25T00:13:39Z</updated>
		<published>2013-01-25T00:13:39Z</published>
		<category scheme="http://www.bio-wire.com" term="Brian L. Wilson" /><category scheme="http://www.bio-wire.com" term="ZLCS" />		<summary type="html"><![CDATA[Shares of Zalicus Inc. (NASDAQ: ZLCS) are struggling to gain any serious traction in the wake of the very weak phase IIb trial results for the drug Synavive reported by the company in September, 2012. Unfortunately, if you check the price action on ZLCS, you can see that many people attempting to play the long side of [...]]]></summary>
		<link rel="replies" type="text/html" href="http://www.bio-wire.com/archives/707#comments" thr:count="0" />
		<link rel="replies" type="application/atom+xml" href="http://www.bio-wire.com/archives/707/feed/atom" thr:count="0" />
		<thr:total>0</thr:total>
	</entry>
		<entry>
		<author>
			<name>The Life Sciences Report</name>
						<uri>http://www.thelifesciencesreport.com/</uri>
					</author>
		<title type="html"><![CDATA[Stephen Brozak: Changing the Way Money Is Made and Diseases Are Cured]]></title>
		<link rel="alternate" type="text/html" href="http://www.bio-wire.com/archives/702" />
		<id>http://www.bio-wire.com/?p=702</id>
		<updated>2013-01-24T19:19:33Z</updated>
		<published>2013-01-24T19:17:57Z</published>
		<category scheme="http://www.bio-wire.com" term="The Life Sciences Report" /><category scheme="http://www.bio-wire.com" term="AMGN" /><category scheme="http://www.bio-wire.com" term="ASTM" /><category scheme="http://www.bio-wire.com" term="ATHX" /><category scheme="http://www.bio-wire.com" term="BTX" /><category scheme="http://www.bio-wire.com" term="CELG" /><category scheme="http://www.bio-wire.com" term="CEMP" /><category scheme="http://www.bio-wire.com" term="CYTX" /><category scheme="http://www.bio-wire.com" term="dndn" /><category scheme="http://www.bio-wire.com" term="DRTX" /><category scheme="http://www.bio-wire.com" term="GERN" /><category scheme="http://www.bio-wire.com" term="NBS" /><category scheme="http://www.bio-wire.com" term="PFE" /><category scheme="http://www.bio-wire.com" term="TSRX" />		<summary type="html"><![CDATA[ Source: George S. Mack of The Life Sciences Report  (1/24/13) &#160; http://www.thelifesciencesreport.com/pub/na/14943 &#160; Stephen Brozak doesn&#8217;t mess around. He focuses on technologies poised to change the way medicine has been practiced for thousands of years. As president of WBB Securities, Brozak is talking to his clientele about revolutionary stem cell therapies that deal with disease in [...]]]></summary>
		<link rel="replies" type="text/html" href="http://www.bio-wire.com/archives/702#comments" thr:count="0" />
		<link rel="replies" type="application/atom+xml" href="http://www.bio-wire.com/archives/702/feed/atom" thr:count="0" />
		<thr:total>0</thr:total>
	</entry>
		<entry>
		<author>
			<name>Brian L. Wilson</name>
					</author>
		<title type="html"><![CDATA[Arena Stumbles On EMA Concerns Over Belviq Ahead Of Launch]]></title>
		<link rel="alternate" type="text/html" href="http://www.bio-wire.com/archives/683" />
		<id>http://www.bio-wire.com/?p=683</id>
		<updated>2013-01-23T16:32:54Z</updated>
		<published>2013-01-23T16:26:24Z</published>
		<category scheme="http://www.bio-wire.com" term="Brian L. Wilson" /><category scheme="http://www.bio-wire.com" term="ARNA" /><category scheme="http://www.bio-wire.com" term="VVUS" />		<summary type="html"><![CDATA[We&#8217;ve seen no shortage of recent volatility in shares of Arena Pharmaceuticals (NASDAQ: ARNA), which moved down over 9.7% just yesterday based on commentary from the company regarding the prospects of its flagship product and weight-loss drug Belviq (lorcaserin) in the European Union. The company&#8217;s statements claim that an advisory committee for the EMA (European Medicines [...]]]></summary>
		<link rel="replies" type="text/html" href="http://www.bio-wire.com/archives/683#comments" thr:count="0" />
		<link rel="replies" type="application/atom+xml" href="http://www.bio-wire.com/archives/683/feed/atom" thr:count="0" />
		<thr:total>0</thr:total>
	</entry>
		<entry>
		<author>
			<name>Brian L. Wilson</name>
					</author>
		<title type="html"><![CDATA[Market Bets On Approval For Hyperion&#8217;s Ravicti On FDA&#8217;s &#8220;Hint&#8221;]]></title>
		<link rel="alternate" type="text/html" href="http://www.bio-wire.com/archives/684" />
		<id>http://www.bio-wire.com/?p=684</id>
		<updated>2013-01-23T16:26:25Z</updated>
		<published>2013-01-23T16:23:57Z</published>
		<category scheme="http://www.bio-wire.com" term="Brian L. Wilson" /><category scheme="http://www.bio-wire.com" term="HPTX" />		<summary type="html"><![CDATA[There were a lot of very bullish moves in the biotech sector last week, including a particularly huge rally inHyperion Therapeutics (NASDAQ: HPTX) which drove the stock up about 33% in the last five trading sessions. Hyperion Therapeutics is focused on the development therapies for orphan diseases and hepatology. Even if biotech stocks are unexplainable in [...]]]></summary>
		<link rel="replies" type="text/html" href="http://www.bio-wire.com/archives/684#comments" thr:count="0" />
		<link rel="replies" type="application/atom+xml" href="http://www.bio-wire.com/archives/684/feed/atom" thr:count="0" />
		<thr:total>0</thr:total>
	</entry>
	</feed>
